{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with a confirmed best response of Complete response (CR) or Partial Response (PR) in participants with measurable disease at study entry. Modified RECIST Version 1.1 criteria is used to determine ORR (ie, CR or PR by IRR assessment and no progression in bone per PCWG3 by IRR assessment).\n\nCR is disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","groups":[{"description":"Oral rucaparib (monotherapy).\n\nRucaparib: Rucaparib will be administered daily.","id":"OG000","title":"Rucaparib"},{"description":"Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).\n\nAbiraterone acetate or Enzalutamide or Docetaxel: Abiraterone acetate and enzalutamide will be administered daily.\n\nDocetaxel will be administered every 3 weeks.","id":"OG001","title":"Abiraterone Acetate or Enzalutamide or Docetaxel"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT Population included all randomized participants (participants with BRCA mutated mCRPC and participants with ATM mutated mCRPC) with measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"From enrollment to primary completion of study (Total follow-up was up to approximately 4 years)","title":"Objective Response Rate (ORR) by IRR in Participants With a BRCA or ATM Alteration Combined","type":"SECONDARY","unitOfMeasure":"Participants"}